[go: up one dir, main page]

HUP9903863A2 - Metalloproteináz-inhibitorok - Google Patents

Metalloproteináz-inhibitorok

Info

Publication number
HUP9903863A2
HUP9903863A2 HU9903863A HUP9903863A HUP9903863A2 HU P9903863 A2 HUP9903863 A2 HU P9903863A2 HU 9903863 A HU9903863 A HU 9903863A HU P9903863 A HUP9903863 A HU P9903863A HU P9903863 A2 HUP9903863 A2 HU P9903863A2
Authority
HU
Hungary
Prior art keywords
metalloproteinase inhibitors
isobutylcinnamide
methylcarbamoyl
solvates
cyclopentyl
Prior art date
Application number
HU9903863A
Other languages
English (en)
Inventor
Christopher Norman Lewis
Fionna Mitchell Martin
Mark Whittaker
Original Assignee
British Biotech Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9523937.2A external-priority patent/GB9523937D0/en
Priority claimed from GBGB9610985.5A external-priority patent/GB9610985D0/en
Application filed by British Biotech Pharmaceuticals Ltd. filed Critical British Biotech Pharmaceuticals Ltd.
Publication of HUP9903863A2 publication Critical patent/HUP9903863A2/hu
Publication of HUP9903863A3 publication Critical patent/HUP9903863A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

A találmány szerinti 2S-ciklőpentil-N4-[2,2-dimetil-1S-(metilkarbamőil)-prőpil]-N1-hidrőxi-3R-izőbűtilszűkcinamid és annaksói, szőlvátjai vagy hidrátjai mátrix metallőprőteináz inhibitőrők. ŕ
HU9903863A 1995-11-23 1996-11-21 Metalloproteinase inhibitors HUP9903863A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9523937.2A GB9523937D0 (en) 1995-11-23 1995-11-23 Metalloproteinase inhibitors
GBGB9610985.5A GB9610985D0 (en) 1996-05-24 1996-05-24 Metalloproteinase inhibitors
PCT/GB1996/002877 WO1997019053A1 (en) 1995-11-23 1996-11-21 Metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
HUP9903863A2 true HUP9903863A2 (hu) 2000-03-28
HUP9903863A3 HUP9903863A3 (en) 2000-11-28

Family

ID=26308164

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903863A HUP9903863A3 (en) 1995-11-23 1996-11-21 Metalloproteinase inhibitors

Country Status (11)

Country Link
US (2) US6127427A (hu)
EP (1) EP0873304B1 (hu)
JP (1) JP2000500761A (hu)
AT (1) ATE205184T1 (hu)
AU (1) AU711804B2 (hu)
CZ (1) CZ292617B6 (hu)
DE (1) DE69615058T2 (hu)
ES (1) ES2164264T3 (hu)
HU (1) HUP9903863A3 (hu)
NZ (1) NZ322553A (hu)
WO (1) WO1997019053A1 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205184T1 (de) * 1995-11-23 2001-09-15 British Biotech Pharm Metalloproteinase inhibitoren
IL128337A0 (en) 1996-09-10 2000-01-31 British Biotech Pharm Cytostatic hydroxamic acid derivatives
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
PL335378A1 (en) * 1997-02-26 2000-04-25 Glaxo Group Ltd Derivatives of inverse hydroxamates as metaloprotease inhibitors
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
GB9818621D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
WO2000012083A1 (en) * 1998-08-26 2000-03-09 Glaxo Group Limited Formamides as therapeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
WO2000038618A2 (en) 1998-12-24 2000-07-06 Du Pont Pharmaceuticals Company SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
GB9918869D0 (en) * 1999-08-10 1999-10-13 British Biotech Pharm Antibacterial agents
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
WO2001027091A1 (en) 1999-10-08 2001-04-19 Du Pont Pharmaceuticals Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
AU1196601A (en) * 1999-10-12 2001-04-23 Board Of Trustees Of The Leland Stanford Junior University Methods of diagnosing and treating urinary incontinence
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
BR0110051A (pt) 2000-04-03 2004-12-07 Bristol Myers Squibb Pharma Co Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
IL151576A0 (en) 2000-04-03 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic lactams as inhibitors of a-beta protein production
WO2001077086A1 (en) 2000-04-11 2001-10-18 Dupont Pharmaceuticals Company SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
AR028606A1 (es) * 2000-05-24 2003-05-14 Smithkline Beecham Corp Nuevos inhibidores de mmp-2/mmp-9
IL147629A0 (en) 2000-06-01 2002-08-14 Bristol Myers Squibb Pharma Co LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6476046B1 (en) 2000-12-04 2002-11-05 Sepracor, Inc. Diazabicyclo[4.3.0]nonanes, and methods of use thereof
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
CN114276231A (zh) * 2021-12-30 2022-04-05 江苏云朴医药新材料科技有限公司 一种4-叔丁基环己基乙酸的合成方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) 1989-08-24 1989-10-04 British Bio Technology Compounds
US5183900A (en) 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5270326A (en) 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration
HUT62263A (en) 1990-12-03 1993-04-28 Celltech Ltd Process for producing peptidyl derivatives and pharmaceutical compositions comprising such compounds as active ingredient
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
WO1992022523A2 (en) 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
US5256657A (en) 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
DK0621270T3 (da) 1991-11-08 2000-07-17 Sankyo Co Piperazinderivater som collagenaseinhibitorer
WO1993020047A1 (en) 1992-04-07 1993-10-14 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9211707D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211706D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
AU666727B2 (en) 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
AU671724B2 (en) 1993-03-16 1996-09-05 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors
WO1994021612A1 (en) 1993-03-18 1994-09-29 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
GB9307956D0 (en) 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
CA2139128A1 (en) 1993-04-27 1994-11-10 Celltech Therapeutics Limited Peptidyl derivatives as metalloproteinase inhibitors
JPH09503492A (ja) 1993-08-02 1997-04-08 セルテック・セラピューティクス・リミテッド スクシンアミド誘導体、それらの調製法及びそれらのゼラチナーゼ及びコラゲナーゼ阻害剤としての使用
DE69405572T2 (de) 1993-08-05 1998-02-12 Syntex (U.S.A.) Inc., Palo Alto, Calif. Matrix-metalloprotease inhibitoren
KR100312097B1 (ko) 1993-08-09 2002-11-13 가네보 가부시키가이샤 아실페닐글리신 유도체 및 그 화합물을 유효성분으로하는,콜라게나제활성증진에기인한질환의예방및치료제
AU687436B2 (en) 1993-08-23 1998-02-26 Immunex Corporation Inhibitors of TNF-alpha secretion
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
ES2144819T3 (es) * 1994-01-20 2000-06-16 British Biotech Pharm L-terc-leucina-2-piridilamida.
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
EP0905126B1 (en) 1994-01-22 2002-12-04 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5514716A (en) 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9404046D0 (en) 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
ATE205184T1 (de) * 1995-11-23 2001-09-15 British Biotech Pharm Metalloproteinase inhibitoren
DE102008040465A1 (de) 2008-07-16 2010-01-21 Robert Bosch Gmbh Werkzeugmaschine, insbesondere Tischkreissäge

Also Published As

Publication number Publication date
JP2000500761A (ja) 2000-01-25
HUP9903863A3 (en) 2000-11-28
CZ159098A3 (cs) 1998-11-11
CZ292617B6 (cs) 2003-11-12
ATE205184T1 (de) 2001-09-15
EP0873304B1 (en) 2001-09-05
EP0873304A1 (en) 1998-10-28
WO1997019053A1 (en) 1997-05-29
AU7633096A (en) 1997-06-11
US6329373B1 (en) 2001-12-11
NZ322553A (en) 1998-12-23
DE69615058D1 (de) 2001-10-11
DE69615058T2 (de) 2002-06-27
AU711804B2 (en) 1999-10-21
US6127427A (en) 2000-10-03
ES2164264T3 (es) 2002-02-16

Similar Documents

Publication Publication Date Title
HUP9903863A2 (hu) Metalloproteináz-inhibitorok
FI904101A0 (fi) 17b-acyl-4-aza-5a-androst-1-en-3-on- som 5a-reduktasinhibitorer.
ATE227274T1 (de) 1,3-diheterozyklische metalloprotease inhibitoren
DZ1966A1 (fr) Combinaison pharmaceutique nouvelle.
FI961809L (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
NO903799L (no) Acat-inhibitorer.
FI913006L (fi) Ny trombocytaggregationsinhibitor.
DE69018998D1 (de) Pneumatischer schlagbohrer.
FI904729A0 (fi) Inhibitorer av retrovirala proteaser.
NO903346D0 (no) Boresikringsventil.
TR199600358A2 (tr) -Adrenerjik agonistleri.
NO910739D0 (no) Sementeringsmateriale for olje, gass- og vannbroenner.
NL1004238A1 (nl) Slijtplaten.
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
NO981019D0 (no) Deodoriserende preparater inneholdende kationiske biopolymerer, aluminiumklorhydrat og esteraseinhibitorer
FR2693911B1 (fr) Nouvelles utilisations d'un appareillage d'électro-anesthésie.
DE69518161D1 (de) Hydraulischer brechhammer
FR2701834B1 (fr) Valve phonatoire autoadhesive.
DE69023975D1 (de) Tandem-montierte, stirnseitige Dichtungen.
NO975534L (no) Imidazo-£1,5|-pyridin-avledete serinproteaseinhibitorer
DE59001163D1 (de) Bohr- oder schlaghammer.
IT1271737B (it) N,n-dimetilamminoetil-beta-(4-idrossi-3,5-di-terzbutilfenil)- propionati
ES2195122T3 (es) Inhibidores de metaloproteinasa.
NO972876D0 (no) Disubstituerte p-fluorbenzolsulfonamider
MY117874A (en) Metalloproteinase inhibitors

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees